AbbVie (ABBV) Tops Q4 EPS by 7c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Abbvie (ABBV) Humira guidance removes overhang - Truist
February 9, 2023 1:39 PM ESTTruist Securities analyst Robyn Karnauskas reiterated a Buy rating and $180.00 price target on Abbvie (NYSE: ABBV) as Humira guidance removes overhang.
The analyst commented, "Following ABBV's 4Q2022 earnings call, we are reiterating our Buy rating as 1) we believe that the guidance provided... More
AbbVie (ABBV) shares rise on earnings beat - prepared for loss of Humira exclusivity
February 9, 2023 10:00 AM ESTAbbVie (NYSE: ABBV) shares are up more than 3% in early Thursday trading after the company topped earnings estimates for the fourth quarter.
Earnings came in at $3.60 per share, $0.07 better than the analyst estimate of $3.53. However, the biotech firm missed the analyst consensus revenue forecast of $15.33 billion, coming in at $15.12 billion.
The company's results included an unfavorable impact of $0.13 per share related to the fourth-quarter 2022 acquired IPR&D and milestones expense.
The... More
